Hubbell Free cash flow decreased by 88.2% to $46.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 303.5%, from $11.40M to $46.00M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 19.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $132.80M | $71.60M | $179.50M | -$35.80M | $168.10M | $194.30M | $180.30M | $80.30M | $192.20M | $159.00M | $283.60M | $51.90M | $205.70M | $188.80M | $364.40M | $11.40M | $220.70M | $253.80M | $388.80M | $46.00M |
| QoQ Change | — | -46.1% | +150.7% | -119.9% | +569.6% | +15.6% | -7.2% | -55.5% | +139.4% | -17.3% | +78.4% | -81.7% | +296.3% | -8.2% | +93.0% | -96.9% | >999% | +15.0% | +53.2% | -88.2% |
| YoY Change | — | — | — | — | +26.6% | +171.4% | +0.4% | +324.3% | +14.3% | -18.2% | +57.3% | -35.4% | +7.0% | +18.7% | +28.5% | -78.0% | +7.3% | +34.4% | +6.7% | +303.5% |